

Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro- oesophageal junction adenocarcinoma

Information for the public

Published: 12 June 2024

www.nice.org.uk

Pembrolizumab (Keytruda) is not normally available on the NHS for untreated locally advanced unresectable or metastatic HER2-positive gastric (stomach) or gastro-oesophageal junction adenocarcinoma. Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS webpage on oesophageal cancer](#) or [stomach cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [GUTS UK](#), 020 7486 0341
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6165-8